Lupin is currently trading at Rs. 1128.70, up by 47.45 points or 4.39% from its previous closing of Rs. 1081.25 on the BSE.
The scrip opened at Rs. 1089.70 and has touched a high and low of Rs. 1132.45 and Rs. 1085.00 respectively. So far 1,54,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1750.00 on 29-Jul-2016 and a 52 week low of Rs. 1036.80 on 05-Jul-2017.
Last one week high and low of the scrip stood at Rs. 1132.45 and Rs. 1036.80 respectively. The current market cap of the company is Rs. 50,999.00 crore.
The promoters holding in the company stood at 46.69%, while Institutions and Non-Institutions held 41.24% and 12.06% respectively.
Pharma Major Lupin has launched its Moxifloxacin Hydrochloride Ophthalmic solution USP, 0.5% (base) having received an approval from the United States Food and Drug Administration (USFDA) earlier.
Moxifloxacin Hydrochloride Ophthalmic solution USP, 0.5% (base), is an AT1 rated generic equivalent of Novartis Pharms Corp.'s Vigamox Ophthalmic solution. It is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the organisms. Vigamox Ophthalmic solution had US sales of $267.9 million as per IMS MAT March 2017.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.